Qlife signs letter of intent with South Korean company Precision Biosensor as part of B2B strategy to enter major markets with Egoo Health, through hospital@home partnerships
Qlife is pleased to announce that it has signed a Letter of Intent (LOI) with leading South Korean company Precision Biosensor, to introduce Egoo Health to the South Korean market. Qlife anticipates finalizing a comprehensive collaboration agreement over the next months. The LOI The agreement is focused on two distinct phases: · Regulatory Approvals: Precision Biosensor will navigate the regulatory landscape to secure product registration from the Korean Ministry of Food and Drug Safety (MFDS) for Egoo Health. · Commercialization in South Korea: Following registrations,